TG Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
07 Septiembre 2023 - 6:30AM
TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael
S. Weiss, the Company’s Chairman and Chief Executive Officer, will
participate in the H.C. Wainwright 25th Annual Global Investment
Conference, being held at the Lotte New York Palace Hotel, in New
York City on September 11 - 13, 2023. The fireside chat is
scheduled to take place on Monday, September 11, 2023, at 10:30 AM
ET.
A live webcast of the fireside chat will be available on the
Events page, located within the Investors & Media section, of
the Company’s website at http://ir.tgtherapeutics.com/events.
ABOUT TG THERAPEUTICSTG Therapeutics is a
fully integrated, commercial stage, biopharmaceutical company
focused on the acquisition, development and commercialization of
novel treatments for B-cell diseases. In addition to a research
pipeline including several investigational medicines, TG has
received approval from the U.S. FDA for BRIUMVI®
(ublituximab-xiiy), for the treatment of adult patients with
relapsing forms of multiple sclerosis, to include clinically
isolated syndrome, relapsing-remitting disease, and active
secondary progressive disease, as well as European Commission (EC)
approval for BRIUMVI to treat adult patients with RMS who have
active disease defined by clinical or imaging features. For more
information, visit www.tgtherapeutics.com, and follow us on
Twitter @TGTherapeutics and on LinkedIn.CONTACT:
Investor Relations: |
Email: ir@tgtxinc.com |
Telephone: 1.877.575.TGTX (8489), Option 4 |
|
Media Relations: |
Email: media@tgtxinc.com |
Telephone: 1.877.575.TGTX (8489), Option 6 |
TG Therapeutics (NASDAQ:TGTX)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
TG Therapeutics (NASDAQ:TGTX)
Gráfica de Acción Histórica
De May 2023 a May 2024